Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is demonstrating promising outcomes in preliminary clinical trials . Recent research https://hypebookmarking.com/story21145123/retatrutide-emerging-investigations-and-possible-medical-roles